SB705498 Proof of Concept Chamber Challenge in Subjects With Non Allergic Rhinitis
Status:
Completed
Trial end date:
2011-04-18
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the pharmacodynamic (PD) effects (Total Symptom Score
(TSS) and its individual components: rhinorrhoea, nasal congestion, post-nasal drip) of
intranasal, repeat dose SB-705498 in non-allergic rhinitis (NAR) patients elicited by a cold
dry air challenge in an environmental exposure chamber (EEC). SB-705498 is a selective
antagonist of the transient receptor potential vanilloid-1 (TRPV1) ligand gated ion channel.
TRPV1 is a cation permeable ion channel that can be activated by several physiological
factors, such as heat, protons (pH), osmotic stress, eicosanoid derivatives, anandamide, and
by products of inflammation, such as histamine, prostaglandins and bradykinin. In the nose,
the local TRPV1 expressing sensory C-fibres are thought to play a key role in the development
of nasal hyper-responsiveness to environmental provocateurs. It has been proposed that
blocking the nasal sensory nerve stimulation may control nasal hyper-responsiveness and
therefore prevent the induction of rhinitis symptoms. In this context, preclinical evidence
supports that targeting TRPV1 by SB-705498 may be an attractive option.
In this study NAR patients will be randomised, in a double blind, placebo controlled cross
over design to receive 14 day repeat doses of 12mg intra-nasal SB-705498 once daily. Whilst
dosing at home, subjects will record symptom scores to document their symptoms. In addition,
during visits to the clinical unit, acoustic rhinometry, quality of life questionnaires and
safety assessments will be monitored.